Who
Cary J. Claiborne
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Adial Pharmaceuticals; Director, LadRx; Chief Financial Officer, Sucampo Pharmaceuticals; former CEO, CFO & Pres., New Generation Biofuels Holdings; Chief Financial Officer, Osiris Therapeutics.
In numbers
- Trades disclosed
- 89
- Buys
- 4
- Sells
- 6
- Bought
- $28K
- Sold
- $735K
- Companies
- 5
- Companies where not an officer
- 1
- First trade
- 27 Sep 2006
- Last trade
- 7 Apr 2026
- Last filed
- 9 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Apr 2026filed 9 Apr 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —37,985 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —37,985 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —138,000 at $0.00 | filing |
| 5 Dec 2024filed 5 Dec 2024 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 25 Mar 2024filed 27 Mar 2024 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 15 Jan 2024filed 29 Jan 2024 | LadRxoption or derivative | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 23 May 2023filed 25 May 2023 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 23 May 2023filed 25 May 2023 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —420,000 at $0.00 | filing |
| 20 Sep 2022filed 20 Sep 2022 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $32K75,000 at $0.42 | filing |
| 19 Sep 2022filed 20 Sep 2022 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $11K25,000 at $0.43 | filing |
| 18 Aug 2022filed 22 Aug 2022 | ADIL Adial PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 23 Feb 2022filed 25 Feb 2022 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,667 at $0.00 | filing |
| 7 Dec 2021filed 8 Dec 2021 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 2 Nov 2021filed 3 Nov 2021 | ADIL Adial Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 16 Dec 2014filed 17 Dec 2014 | Sucampo Pharmaceuticals | SEC FORM 4 Code M | $175K42,900 at $4.07 | filing |
| 16 Dec 2014filed 17 Dec 2014 | Sucampo Pharmaceuticals | SEC FORM 4 Sold | $554K42,900 at $12.91 | filing |
| 16 Dec 2014filed 17 Dec 2014 | Sucampo Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —42,900 at $0.00 | filing |
| 15 Dec 2014filed 17 Dec 2014 | Sucampo Pharmaceuticals | SEC FORM 4 Code M | $29K7,100 at $4.07 | filing |
| 15 Dec 2014filed 17 Dec 2014 | Sucampo Pharmaceuticals | SEC FORM 4 Sold | $92K7,100 at $12.89 | filing |
| 15 Dec 2014filed 17 Dec 2014 | Sucampo Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —7,100 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.